Aleksandra Gentry‐Maharaj
YOU?
Author Swipe
View article: Synolitic Graph Neural Networks of High-Dimensional Proteomic Data Enhance Early Detection of Ovarian Cancer
Synolitic Graph Neural Networks of High-Dimensional Proteomic Data Enhance Early Detection of Ovarian Cancer Open
Background: Ovarian cancer is characterized by high mortality rates, primarily due to diagnosis at late stages. Current biomarkers, such as CA125, have demonstrated limited efficacy for early detection. While high-dimensional proteomics of…
View article: Extracellular vesicle and particle-based blood test for ovarian cancer screening of average risk population: a promising nested case control study using preclinical samples
Extracellular vesicle and particle-based blood test for ovarian cancer screening of average risk population: a promising nested case control study using preclinical samples Open
The EVP-based blood test exhibits high sensitivity and specificity in detecting HGSC in preclinical samples, supporting its further evaluation as a potential annual screening tool for OC in average-risk women.
View article: Methylation dynamics in the decades preceding acute myeloid leukaemia
Methylation dynamics in the decades preceding acute myeloid leukaemia Open
DNA methylation is emerging as a highly sensitive and specific marker of cancer initiation and progression. How these cancerspecific methylation changes are established in the decades before cancer, however, remains largely unknown. Here, …
View article: Advancing Cervical Cancer Prevention Equity: Innovations in Self-Sampling and Digital Health Technologies Across Healthcare Settings
Advancing Cervical Cancer Prevention Equity: Innovations in Self-Sampling and Digital Health Technologies Across Healthcare Settings Open
Cervical cancer causes 350,000 deaths annually, with 90% occurring in low- and middle-income countries (LMICs), despite being largely preventable through vaccination and screening. This review examines innovative approaches to address scre…
View article: Table S3 from Patterns of Associations with Epidemiologic Factors by High-Grade Serous Ovarian Cancer Gene Expression Subtypes
Table S3 from Patterns of Associations with Epidemiologic Factors by High-Grade Serous Ovarian Cancer Gene Expression Subtypes Open
This table shows the associations between epidemiologic risk factors and HGSC subtypes, restricted to White cases and controls
View article: Figure S1 from Patterns of Associations with Epidemiologic Factors by High-Grade Serous Ovarian Cancer Gene Expression Subtypes
Figure S1 from Patterns of Associations with Epidemiologic Factors by High-Grade Serous Ovarian Cancer Gene Expression Subtypes Open
Distribution of subtype proportions by subtype assignment
View article: Table S2 from Patterns of Associations with Epidemiologic Factors by High-Grade Serous Ovarian Cancer Gene Expression Subtypes
Table S2 from Patterns of Associations with Epidemiologic Factors by High-Grade Serous Ovarian Cancer Gene Expression Subtypes Open
This table shows the associations between epidemiologic factors and HGSC subtypes restricted to HGSC cases with probability of subtype assignment >80%.
View article: Data from Patterns of Associations with Epidemiologic Factors by High-Grade Serous Ovarian Cancer Gene Expression Subtypes
Data from Patterns of Associations with Epidemiologic Factors by High-Grade Serous Ovarian Cancer Gene Expression Subtypes Open
Background:Ovarian high-grade serous carcinomas (HGSC) comprise four distinct molecular subtypes based on mRNA expression patterns, with differential survival. Understanding risk factor associations is important to elucidate the etiology o…
View article: Table S1 from Patterns of Associations with Epidemiologic Factors by High-Grade Serous Ovarian Cancer Gene Expression Subtypes
Table S1 from Patterns of Associations with Epidemiologic Factors by High-Grade Serous Ovarian Cancer Gene Expression Subtypes Open
This table shows the availability of epidemiologic factors used in the analyses across the different studies.
View article: Patterns of Associations with Epidemiologic Factors by High-Grade Serous Ovarian Cancer Gene Expression Subtypes
Patterns of Associations with Epidemiologic Factors by High-Grade Serous Ovarian Cancer Gene Expression Subtypes Open
Background: Ovarian high-grade serous carcinomas (HGSC) comprise four distinct molecular subtypes based on mRNA expression patterns, with differential survival. Understanding risk factor associations is important to elucidate the etiology …
View article: The Safety and Efficacy Profile of Magnesium‐Based Bioresorbable Coronary Stents as Compared to Poly‐L‐Lactic Acid–Based Bioresorbable and Contemporary Drug‐Eluting Coronary Stents—A Systematic Review
The Safety and Efficacy Profile of Magnesium‐Based Bioresorbable Coronary Stents as Compared to Poly‐L‐Lactic Acid–Based Bioresorbable and Contemporary Drug‐Eluting Coronary Stents—A Systematic Review Open
Background: Bioresorbable coronary stents (BRS) were designed with the aim of reducing the risk of late adverse events of permanent drug‐eluting stents (DES) by dissolving once vessel patency had been restored and the requirement for acute…
View article: Polygenic score distribution differences across European ancestry populations: implications for breast cancer risk prediction
Polygenic score distribution differences across European ancestry populations: implications for breast cancer risk prediction Open
Our results demonstrate that PRS distribution differs even within European ancestry populations leading to underestimation or overestimation of risk in specific European countries, which could potentially influence clinical management of s…
View article: Improving Accessibility of Cervical Cancer Screening: A Global Perspective on Self-Sampling and Digital Innovation
Improving Accessibility of Cervical Cancer Screening: A Global Perspective on Self-Sampling and Digital Innovation Open
Cervical cancer causes 350,000 deaths annually, with 90% occurring in low and middle-income countries (LMICs), despite being largely preventable through vaccination and screening. This review examines innovative approaches to address scree…
View article: Immunological and molecular features of the tumor microenvironment of long-term survivors of ovarian cancer
Immunological and molecular features of the tumor microenvironment of long-term survivors of ovarian cancer Open
BACKGROUNDDespite an overall poor prognosis, about 15% of patients with advanced-stage tubo-ovarian high-grade serous carcinoma (HGSC) survive 10 or more years after standard treatment.METHODSWe evaluated the tumor microenvironment of this…
View article: Identification of a serum proteomic biomarker panel using diagnosis specific ensemble learning and symptoms for early pancreatic cancer detection
Identification of a serum proteomic biomarker panel using diagnosis specific ensemble learning and symptoms for early pancreatic cancer detection Open
Background The grim (<10% 5-year) survival rates for pancreatic ductal adenocarcinoma (PDAC) are attributed to its complex intrinsic biology and most often late-stage detection. The overlap of symptoms with benign gastrointestinal conditio…
View article: Supplementary Table S4 from Concurrent RB1 Loss and <i>BRCA</i> Deficiency Predicts Enhanced Immunologic Response and Long-term Survival in Tubo-ovarian High-grade Serous Carcinoma
Supplementary Table S4 from Concurrent RB1 Loss and <i>BRCA</i> Deficiency Predicts Enhanced Immunologic Response and Long-term Survival in Tubo-ovarian High-grade Serous Carcinoma Open
Supplementary Table S4. Differential gene expression analysis comparing transcriptomes of tumors based on BRCA and RB1 alteration status.
View article: Supplementary Figure S10 from Concurrent RB1 Loss and <i>BRCA</i> Deficiency Predicts Enhanced Immunologic Response and Long-term Survival in Tubo-ovarian High-grade Serous Carcinoma
Supplementary Figure S10 from Concurrent RB1 Loss and <i>BRCA</i> Deficiency Predicts Enhanced Immunologic Response and Long-term Survival in Tubo-ovarian High-grade Serous Carcinoma Open
Supplementary Figure S10. Immune cell subsets inferred from gene expression data by combined homologous recombination deficiency and RB1 status.
View article: Supplementary Table S17 from Concurrent RB1 Loss and <i>BRCA</i> Deficiency Predicts Enhanced Immunologic Response and Long-term Survival in Tubo-ovarian High-grade Serous Carcinoma
Supplementary Table S17 from Concurrent RB1 Loss and <i>BRCA</i> Deficiency Predicts Enhanced Immunologic Response and Long-term Survival in Tubo-ovarian High-grade Serous Carcinoma Open
Supplementary Table S17. Half maximum inhibitory concentrations (IC50) for cisplatin (72 hours), paclitaxel (72 hours), or olaparib (120 hours) in HGSC cell lines with innate RB1 and/or BRCA1 alterations.
View article: Supplementary Table S3 from Concurrent RB1 Loss and <i>BRCA</i> Deficiency Predicts Enhanced Immunologic Response and Long-term Survival in Tubo-ovarian High-grade Serous Carcinoma
Supplementary Table S3 from Concurrent RB1 Loss and <i>BRCA</i> Deficiency Predicts Enhanced Immunologic Response and Long-term Survival in Tubo-ovarian High-grade Serous Carcinoma Open
Supplementary Table S3. Number of RNA-seq primary tumor samples by library type and alteration group.
View article: Supplementary Figure S9 from Concurrent RB1 Loss and <i>BRCA</i> Deficiency Predicts Enhanced Immunologic Response and Long-term Survival in Tubo-ovarian High-grade Serous Carcinoma
Supplementary Figure S9 from Concurrent RB1 Loss and <i>BRCA</i> Deficiency Predicts Enhanced Immunologic Response and Long-term Survival in Tubo-ovarian High-grade Serous Carcinoma Open
Supplementary Figure S9. Bars indicate the number of differentially expressed genes (Benjamini-Hochberg adjusted P value < 0.05) between HGSC tumors grouped by HRD and/or RB1 status as shown.
View article: Supplementary Table S8 from Concurrent RB1 Loss and <i>BRCA</i> Deficiency Predicts Enhanced Immunologic Response and Long-term Survival in Tubo-ovarian High-grade Serous Carcinoma
Supplementary Table S8 from Concurrent RB1 Loss and <i>BRCA</i> Deficiency Predicts Enhanced Immunologic Response and Long-term Survival in Tubo-ovarian High-grade Serous Carcinoma Open
Supplementary Table S8. Antibodies and reagents.
View article: Supplementary Table S14 from Concurrent RB1 Loss and <i>BRCA</i> Deficiency Predicts Enhanced Immunologic Response and Long-term Survival in Tubo-ovarian High-grade Serous Carcinoma
Supplementary Table S14 from Concurrent RB1 Loss and <i>BRCA</i> Deficiency Predicts Enhanced Immunologic Response and Long-term Survival in Tubo-ovarian High-grade Serous Carcinoma Open
Supplementary Table S14. Multivariable adjusted association of molecular alterations and overall survival in ENOC among patients with grade information.
View article: Table 1 from Concurrent RB1 Loss and <i>BRCA</i> Deficiency Predicts Enhanced Immunologic Response and Long-term Survival in Tubo-ovarian High-grade Serous Carcinoma
Table 1 from Concurrent RB1 Loss and <i>BRCA</i> Deficiency Predicts Enhanced Immunologic Response and Long-term Survival in Tubo-ovarian High-grade Serous Carcinoma Open
Clinicopathologic characteristics and RB1 expression patterns across histotypes.
View article: Table 2 from Concurrent RB1 Loss and <i>BRCA</i> Deficiency Predicts Enhanced Immunologic Response and Long-term Survival in Tubo-ovarian High-grade Serous Carcinoma
Table 2 from Concurrent RB1 Loss and <i>BRCA</i> Deficiency Predicts Enhanced Immunologic Response and Long-term Survival in Tubo-ovarian High-grade Serous Carcinoma Open
Multivariate analysis of molecular alterations and OS in patients with HGSC and ENOC.
View article: Supplementary Figure S6 from Concurrent RB1 Loss and <i>BRCA</i> Deficiency Predicts Enhanced Immunologic Response and Long-term Survival in Tubo-ovarian High-grade Serous Carcinoma
Supplementary Figure S6 from Concurrent RB1 Loss and <i>BRCA</i> Deficiency Predicts Enhanced Immunologic Response and Long-term Survival in Tubo-ovarian High-grade Serous Carcinoma Open
Supplementary Figure S6. Mutational signatures in homologous recombination deficiency and RB1 subgroups.
View article: Supplementary Table S1 from Concurrent RB1 Loss and <i>BRCA</i> Deficiency Predicts Enhanced Immunologic Response and Long-term Survival in Tubo-ovarian High-grade Serous Carcinoma
Supplementary Table S1 from Concurrent RB1 Loss and <i>BRCA</i> Deficiency Predicts Enhanced Immunologic Response and Long-term Survival in Tubo-ovarian High-grade Serous Carcinoma Open
Supplementary Table S1. Details of participating Ovarian Tumor Tissue Analysis (OTTA) consortium studies and ethics approvals.
View article: Supplementary Table S14 from Concurrent RB1 Loss and <i>BRCA</i> Deficiency Predicts Enhanced Immunologic Response and Long-term Survival in Tubo-ovarian High-grade Serous Carcinoma
Supplementary Table S14 from Concurrent RB1 Loss and <i>BRCA</i> Deficiency Predicts Enhanced Immunologic Response and Long-term Survival in Tubo-ovarian High-grade Serous Carcinoma Open
Supplementary Table S14. Multivariable adjusted association of molecular alterations and overall survival in ENOC among patients with grade information.
View article: Supplementary Figure S4 from Concurrent RB1 Loss and <i>BRCA</i> Deficiency Predicts Enhanced Immunologic Response and Long-term Survival in Tubo-ovarian High-grade Serous Carcinoma
Supplementary Figure S4 from Concurrent RB1 Loss and <i>BRCA</i> Deficiency Predicts Enhanced Immunologic Response and Long-term Survival in Tubo-ovarian High-grade Serous Carcinoma Open
Supplementary Figure S4. HGSC cell lines with innate RB1 and/or BRCA1 alterations.
View article: Supplementary Figure S3 from Concurrent RB1 Loss and <i>BRCA</i> Deficiency Predicts Enhanced Immunologic Response and Long-term Survival in Tubo-ovarian High-grade Serous Carcinoma
Supplementary Figure S3 from Concurrent RB1 Loss and <i>BRCA</i> Deficiency Predicts Enhanced Immunologic Response and Long-term Survival in Tubo-ovarian High-grade Serous Carcinoma Open
Supplementary Figure S3. Overall survival by combined RB1 and p53 expression in ENOC, and RB1 protein expression and BRCA status in HGSC.
View article: Supplementary Figure S3 from Concurrent RB1 Loss and <i>BRCA</i> Deficiency Predicts Enhanced Immunologic Response and Long-term Survival in Tubo-ovarian High-grade Serous Carcinoma
Supplementary Figure S3 from Concurrent RB1 Loss and <i>BRCA</i> Deficiency Predicts Enhanced Immunologic Response and Long-term Survival in Tubo-ovarian High-grade Serous Carcinoma Open
Supplementary Figure S3. Overall survival by combined RB1 and p53 expression in ENOC, and RB1 protein expression and BRCA status in HGSC.